The Chronic Urticaria Or Hives drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Urticaria Or Hives. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued products.
GlobalData tracks 61 drugs in development for Chronic Urticaria Or Hives by 59 companies/universities/institutes. The top development phase for Chronic Urticaria Or Hives is phase ii with 20 drugs in that stage. The Chronic Urticaria Or Hives pipeline has 60 drugs in development by companies and one by universities/ institutes. Some of the companies in the Chronic Urticaria Or Hives pipeline products market are: Invea Therapeutics, Allakos and BiosanaPharma.
The key targets in the Chronic Urticaria Or Hives pipeline products market include Immunoglobulin E (IgE) , Histamine H1 Receptor (HRH1), and Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2).
The key mechanisms of action in the Chronic Urticaria Or Hives pipeline product include Immunoglobulin E (IgE) Inhibitor with 14 drugs in Pre-Registration. The Chronic Urticaria Or Hives pipeline products include nine routes of administration with the top ROA being Oral and eight key molecule types in the Chronic Urticaria Or Hives pipeline products market including Monoclonal Antibody, and Small Molecule.
Chronic Urticaria Or Hives overview
Chronic urticaria, also known as hives, are outbreaks of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin’s surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol, and insect bites and stings. Treatment includes antihistamines and corticosteroids.
For a complete picture of Chronic Urticaria Or Hives’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
